MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to temozolomide in human glioblastoma

<i>Background:</i> Glioblastomas (GBMs) present remarkable metabolism reprograming, in which many cells display the “Warburg effect”, with the production of high levels of lactate that are extruded to the tumour microenvironment by monocarboxylate transporters (MCTs). We described previo...

Full description

Bibliographic Details
Main Author: Miranda-Gonçalves, Vera (author)
Other Authors: Gonçalves, Celine Saraiva (author), Granja, Sara Costa (author), Castro, Joana Isabel Martins Cosme Vieira (author), Reis, Rui M. (author), Costa, Bruno M. (author), Baltazar, Fátima (author)
Format: article
Language:eng
Published: 2021
Subjects:
Monocarboxylate transporters
Glioblastoma
Lactate
Warburg effect
Prognostic biomarker
Science & Technology
Online Access:http://hdl.handle.net/1822/74346
Country:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/74346

Internet

http://hdl.handle.net/1822/74346

Similar Items